Gabapentin and Application site swelling - a phase IV clinical study of FDA data

Summary:

Application site swelling is reported as a side effect among people who take Gabapentin (gabapentin), especially for people who are female, 60+ old, also take Temazepam, and have Neuropathy peripheral.

The phase IV clinical study analyzes which people have Application site swelling when taking Gabapentin. It is created by eHealthMe based on reports of 313,421 people who have side effects when taking Gabapentin from the FDA, and is updated regularly.

What is Gabapentin?

Gabapentin has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 322,983 Gabapentin users. Check the latest studies of Gabapentin.

What is Application site swelling?

Application site swelling is found to be associated with 220 drugs and 477 conditions by eHealthMe. Check the latest studies of Application site swelling.

On Jul, 19, 2026

313,421 people reported to have side effects when taking Gabapentin.
Among them, 27 people (0.01%) have Application site swelling.

Could Gabapentin cause Application site swelling?

Among these 27 people:

What is the gender of people who have Application site swelling when taking Gabapentin? *

female: 52 %
male: 48 %

What is the age of people who have Application site swelling when taking Gabapentin? *

What are other drugs people take besides Gabapentin? *

What are other side effects people have besides Application site swelling? *

Application Site Erythema (redness of the skin at application site): 14 people, 51.85%
Application Site Pruritus (application site severe itching of the skin): 8 people, 29.63%
Application Site Irritation: 5 people, 18.52%
Application Site Pain: 4 people, 14.81%
Dizziness: 3 people, 11.11%
Hypersensitivity: 2 people, 7.41%
Rashes (redness): 2 people, 7.41%
Itching: 2 people, 7.41%
Purulence (containing pus): 2 people, 7.41%
Incision Site Infection (infection at incision site): 2 people, 7.41%

What are the existing conditions these people have? *

Back Pain: 3 people, 11.11%
Quit Smoking: 3 people, 11.11%
Pain In Extremity: 3 people, 11.11%
Neuropathy Peripheral (surface nerve damage): 3 people, 11.11%
Wound: 2 people, 7.41%
Movement Disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness): 2 people, 7.41%
Cardiac Disorder: 2 people, 7.41%
Depression: 2 people, 7.41%
Fibromyalgia (a long-term condition which causes pain all over the body): 2 people, 7.41%
Gastric Ulcer (stomach ulcer): 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Gabapentin and have Application site swelling?

- Check whether Application site swelling is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gabapentin:

Gabapentin (322,983 reports)

Browse all side effects of Gabapentin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site swelling:

Application site swelling (220 drugs)

Browse all the conditions that are associated with Application site swelling:

Application site swelling (477 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gabapentin) and Gabapentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.